28 results
Thumbnail

D3.80 - Molecular allergy profiling of sensitization in adult patients with asthma in real practice

Thumbnail

D3.84 - Patterns of Sensitization to Artemisia and Ambrosia Pollen in Ukraine

Thumbnail

D3.90 - Outcomes of Beta-Lactam Allergy Evaluation in Patients with Suspected Hypersensitivity: One-Year Experience

Thumbnail

D3.78 - Association between lipocalin sensitization and clinical symptoms: Evidence for cross-reactivity

Thumbnail

D3.81 - Allergic Contact Dermatitis Induced by Transdermal Estradiol Hormone Replacement Therapy in a Postmenopausal Patient: A Case Report

Thumbnail

D3.82 - Conceptualization of a questionnaire for clinical diagnosis of house dust mite’s allergy

Thumbnail

D3.83 - A Case Report of Fenofibrate-Induced Fixed Drug Eruption Documented by Patch Testing and Oral Provocation

Thumbnail

D3.86 - ALEX versus ISAC. The same story or an improvement for allergologic molecular diagnostic?

Thumbnail

D3.87 - Evaluation of CD63 as a Marker of Basophil Degranulation in the Assessment of IgE-mediated Allergic Immune Responses

Thumbnail

D3.89 - Decoding a Triple Pediatric Food Allergy Phenotype Using Component-Resolved Diagnostics: Severe CMPA, Alpha-Gal, and PR-10–Mediated PFAS

Thumbnail

D3.91 - Molecular Profiling of Shrimp Allergy in Tunisia: The Role of Tropomyosin and Component-Resolved Diagnosis

Thumbnail

D3.92 - Precision Allergy Diagnostics in Tunisia: Integrating Molecular Allergology into the Management of Respiratory and Food Allergies

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child

Thumbnail

D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD

Thumbnail

D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis